Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Xeltis logo — Transformative vascular implants. Addressing major life-thr...

Xeltis

Transformative vascular implants. Addressing major life-threatening diseases, backed by Nobel-winning science.

Founded 2006 The Netherlands The Netherlands 84 employees Undisclosed Total: $195.50M Health Care, Health and Wellness +1

General Information

Company Name Xeltis
Founded Year 2006
Location The Netherlands The Netherlands +1
Employees 84
Industries Health Care, Health and Wellness, Medical Devices
Funding Stage Undisclosed
Social

Get notified when Xeltis moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Xeltis

Xeltis, a pioneering force in Health Care and Medical Devices, is transforming treatments for major life-threatening diseases. Founded in 2006, this company is headquartered in The Netherlands and is developing artificial vessels and valves that gradually integrate with patients' own living tissue. Grounded in Nobel-winning science, Xeltis is addressing critical needs in vascular health.

The most recent funding round, a €12.50M Series D investment on 14 August 2023, showcases strong backing from an impressive consortium of investors, including Kurma Partners, VI Partners, DaVita Venture Group, European Innovation Council, Ysios Capital, China Grand Pharmaceutical and Healthcare Holdings, and EQT Life Sciences.

This substantial financial endorsement underlines Xeltis' innovative potential and reflects significant confidence in their disruptive approach to health care solutions.

Taxonomy: transformative vascular implants, artificial blood vessels, polymer-based restorative devices, cardiovascular treatment, hemodialysis vascular access, coronary artery bypass graft surgery, pulmonary heart valves, clinical-stage medical devices, university spin-offs, venture capital funding, nobel-winning science, advanced polymer technology, tissue regeneration

Services & Products

Development of novel vascular implants
Research and development in polymer-based medical devices
Clinical trial operations
Vascular access solutions for dialysis
Cardiovascular surgery innovations

Target Customers

Cardiovascular surgeons Hospitals and healthcare providers Patients requiring vascular surgeries Renal dialysis centers

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Undisclosed •••••• 7
Investor Investor Investor Investor Investor
•••• •••• 		28 Jul 2026
Series D •••••• 7
Investor Investor Investor Investor Investor Investor
•••• •••• 		14 Aug 2023
Series D •••••• 4
Investor Investor Investor
•••• •••• 		21 Feb 2023
Series D •••••• 1
Investor
09 Aug 2022
Grant •••••• 1
Investor
21 Dec 2021

View All 11 Funding Rounds

Latest News

View All
Axelera AI and Xeltis secure EU scaleup funding — Ioplus.nl
Axelera AI and Xeltis secure EU scaleup funding
Ioplus.nl Apr 03, 2025
How EQT uses AI to see the startup world differently — Tech
How EQT uses AI to see the startup world differently
Tech Nov 20, 2025
Dutch-US MedTech Xeltis raises €20.5 million to advance artificial vessels and valves replaced by pa... — Eu-startups
Dutch-US MedTech Xeltis raises €20.5 million to advance artificial vessels and valves replaced by patients’ own tissue
Eu-startups Jul 28, 2026

Xeltis Alternatives & Competitors

View All Alternatives
Xeltis vs
RUA Life Sciences plc
RUA Life Sciences plc United Kingdom

Improving the lives of patients by enabling medical devices with Elast-Eon, the world's leading impl...

20 employees
Medical Devices
Compare Xeltis vs RUA Life Sciences plc
Xeltis vs
Shape Memory Medical Inc.
Shape Memory Medical Inc. United States

Smart polymer. Smart embolization. Smart choice.

Series C
46 employees
Health Care, Health and Wellness
Compare Xeltis vs Shape Memory Medical Inc.
Xeltis vs
Hicicare
Hicicare

Pioneering the future of interventional medical devices for comprehensive vascular care

Series A
Manufacturing, Medical Devices
Compare Xeltis vs Hicicare
View all alternatives

FAQ About Xeltis

Transformative vascular implants. Addressing major life-threatening diseases, backed by Nobel-winning science.
Xeltis was founded in 2006.
Xeltis is headquartered in The Netherlands.
Xeltis operates in the following industries: Health Care, Health and Wellness, Medical Devices.
Xeltis has approximately 84 employees.
Xeltis has completed 11 funding rounds, raising a total of $195.50M. The latest funding stage is Undisclosed.
Xeltis offers: Development of novel vascular implants, Research and development in polymer-based medical devices, Clinical trial operations, Vascular access solutions for dialysis, Cardiovascular surgery innovations.
Top alternatives and competitors to Xeltis include RUA Life Sciences plc, Shape Memory Medical Inc., Hicicare, Skynor Medical, Ande Healthcare. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Xeltis and RUA Life Sciences plc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Xeltis and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy